REGN's strong fundamentals, including robust revenue growth from Eylea and Dupixent, offset near-term patent expiry concerns. Technicals show support at $850, with RSI suggesting neutral momentum.

Market sentiment is mixed, with REGN's M&A discipline viewed positively, but patent expiry risks weigh on long-term growth perceptions. Recent price swings reflect uncertainty, but institutional interest remains steady.

Patent expiries for key assets pose a long-term risk, but REGN's pipeline and cash flow provide resilience. The cautious M&A stance reduces overpayment risks, supporting a stable outlook.

REGN's 50-day moving average holds above $870, but declining volume signals weakening momentum. MACD crossover suggests potential bearish pressure in the short term.